A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
Publication
, Conference
Khasraw, M; McDonald, KL; Rosenthal, M; Lwin, Z; Ashley, DM; Wheeler, H; Barnes, E; Koh, E-S; Foote, MC; Buckland, M; Fisher, L; Leonard, R ...
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
2045 / 2045
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McDonald, K. L., Rosenthal, M., Lwin, Z., Ashley, D. M., Wheeler, H., … Simes, J. (2018). A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). In Journal of Clinical Oncology (Vol. 36, pp. 2045–2045). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2045
Khasraw, Mustafa, Kerrie Leanne McDonald, Mark Rosenthal, Zarnie Lwin, David M. Ashley, Helen Wheeler, Elizabeth Barnes, et al. “A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).” In Journal of Clinical Oncology, 36:2045–2045. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2045.
Khasraw M, McDonald KL, Rosenthal M, Lwin Z, Ashley DM, Wheeler H, et al. A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2045–2045.
Khasraw, Mustafa, et al. “A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2045–2045. Crossref, doi:10.1200/jco.2018.36.15_suppl.2045.
Khasraw M, McDonald KL, Rosenthal M, Lwin Z, Ashley DM, Wheeler H, Barnes E, Koh E-S, Foote MC, Buckland M, Fisher L, Leonard R, Hall M, Yip S, Simes J. A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2045–2045.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
2045 / 2045
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences